You are here : Home > Research entities > DMTS > Molecular engineering for Heal ... > In vivo proof of concept and biodistribution studies


In vivo proof of concept and biodistribution studies

Published on 29 August 2022

​In order to perform in vivo proof of concept of the potency of the molecules studied in our laboratory, we have developed an expertise in animal models to evaluate their physiological impact, in particular on cardiovascular and renal physiology or for their anti-nociceptive property. In addition, their biodistribution within the body or their safety/toxicity profile can be evaluated. For this purpose, a wide range of materials and expertise is accessible within our rodent facilities (Servent et al., 2021):

  • Syringe/cannula/osmotic pump… to explore and compare various route of administration (intravenous, intraperitoneal, subcutaneous, intranasal, intra-tracheal, intracerebroventricular),
  • Metabolic cages in order to evaluate elimination of molecule by urine and feces over time,
  • BioDAQ food intake monitoring system to collect and record consumption of individual animal,
  • Isoflurane anaesthetic stations enabling refinement of experimental procedures,
  • Surgical expertise allowing the development of pathological study models,
  • Authorization for the administration of radiolabeled molecules in rodents to observe (by digital autoradiography) and quantify (by scintillation) tissue distribution of molecules over time and characterize their pharmacokinetic properties.

Biodistribution analysis using digital autoradiography. Lung distribution of radiolabeled nanoparticle 3 months after intra-tracheal administration in mouse (left)
and biodistribution of 3H-pinnatoxin-G in rat embryos after intravenous injection of the toxin in pregnant rats (right).